Neuronetics Set to Join Russell 2000® Index

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) announced its inclusion in the Russell 2000 Index effective June 28, 2021, following the annual Russell indexes reconstitution. This recognition is based on the company's market capitalization as of May 7. The Russell index membership enhances Neuronetics' visibility among investors and validates its efforts to create shareholder value through its NeuroStar Advanced Therapy System, aimed at improving mental health outcomes. Approximately $10.6 trillion in assets are benchmarked against Russell indexes, making this a significant milestone for the company.

Positive

• Inclusion in Russell 2000 Index enhances visibility among institutional investors.
• Validates efforts to create value for shareholders.
• Demonstrates market capitalization growth, capturing investment interest.

Negative

• None.

MALVERN, Pa., June 23, 2021 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that the company will be added to the Russell 2000® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, according to a preliminary list of additions posted June 4.

Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 7, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

“We are very pleased to be included in the Russell 2000, which we believe will increase our visibility within the investment community,” said Keith Sullivan, President and Chief Executive Officer of Neuronetics, Inc. “Our inclusion validates efforts to create value for our stockholders while we execute our strategy to bring the benefits of NeuroStar Advanced Therapy for Mental Health to patients suffering from depression and other mental health conditions.”

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell’s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Neuronetics

Neuronetics, Inc. is a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its commercial product, the NeuroStar® Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system is cleared by the United States Food and Drug Administration, or FDA, for the treatment of major depressive disorder in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. NeuroStar is also available in other parts of the world, including Japan, where it is listed under Japan’s national health insurance. Additional information can be found at www.neuronetics.com.

About FTSE Russell

FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. For more information, visit www.ftserussell.com.

Investor Contact:

Mike Vallie or Mark Klausner
Westwicke Partners
443-213-0499
ir@neuronetics.com

Media Contact:

Chelsey Manko
Vault Communications
610-455-2778
cmanko@vaultcommunications.com

FAQ

When will Neuronetics be added to the Russell 2000 Index?

Neuronetics will be added to the Russell 2000 Index effective June 28, 2021.

What is the significance of Neuronetics joining the Russell 2000 Index?

Joining the Russell 2000 Index increases Neuronetics' visibility and credibility among investors.

Why was Neuronetics included in the Russell indexes?

Neuronetics was included based on its market capitalization as of May 7, during the annual Russell indexes reconstitution.

What is the market capitalization of Neuronetics?

The specific market capitalization figure is not provided in the PR, but it is sufficient to qualify for inclusion in the Russell 2000 Index.